Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

35.86 -1.06 (-2.87%)
Streaming Delayed Price Updated: 2:24 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
Exposures Product Safety
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
Peering Into Exelixis's Recent Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
Via Benzinga
Looking Into Exelixis's Recent Short Interest
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
What 25 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Is This The Beginning? Insights On Bearish Distribution Patterns
Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
2 Stocks to Buy With Less Than $40
Via The Motley Fool
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Why Exelixis Stock Trounced the Market on Thursday
Via The Motley Fool
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma. 
Via Benzinga
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter. 
Via Stocktwits
Bullish Setups
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Posts 63.7% Profit Surge
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain. 
Via The Motley Fool
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Earnings Scheduled For February 11, 2025
Via Benzinga
NASDAQ:EXEL: good value for what you're paying.
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Exelixis, Inc.
Via Business Wire
Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced.
Uncover the potential of EXELIXIS INC, a growth stock reasonably priced. NASDAQ:EXEL is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.